Noriyuki Ebi

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

Kenji Tamura, Isamu Okamoto, Tatsuhiko Kashii et al. · British Journal of Cancer · 2008 · 203 citations · Full text

Detection of the T790M mutation of <i>EGFR</i> in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)

Takayuki Takahama, Kazuko Sakai, Masayuki Takeda et al. · Oncotarget · 2016 · 71 citations · Full text

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

Hiroki Izumi, Shingo Matsumoto, Jie Liu et al. · Nature · 2021 · 68 citations · Full text

Oncogenic Agent, Medicine, Non‐small‐cell Lung Cancer +10

A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L)

Hiroyuki Yamaguchi, Kazushige Wakuda, Minoru Fukuda et al. · Journal of Thoracic Oncology · 2021 · 67 citations · Full text

Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L)

Ryoji Kato, Hidetoshi Hayashi, Yasutaka Chiba et al. · Journal for ImmunoTherapy of Cancer · 2020 · 61 citations · Full text